Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with Concurrent Chemoradiotherapy for Recurrent Nasopharyngeal Carcinoma
NCT04992988Phase 2Unknown
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Jun 2020
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in nasopharyngeal carcinoma (NPC), sponsored by Cancer Hospital of Guangxi Medical University. Status: unknown.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04992988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04992988.